NCT00667082 - NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Non-Small Cell Lung CancerPancreatic CancerMelanomaLymphomaMultiple Myeloma

Interventions

DRUG

NPI-0052 (marizomib) + vorinostat

"NPI-0052 IV injection over 1 to 10 minutes at doses ranging from 0.15 to 0.7 mg/m2 on Days 1, 8, and 15 of each 28-day Cycle~Oral vorinostat 300 mg was administered with food on Days 1 to 16 of each 28-day Cycle"

Trial Locations (3)

5000

Royal Adelaide Hospital, Adelaide

5011

The Queen Elizabeth Hospital, Woodville South

6009

Sir Charles Gairdner Hospital and University of Western Australia, Nedlands